Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.kilitch.com | |
Market Cap | 626.97 Cr. | |
Enterprise Value(EV) | 646.34 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 9.06 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 43.03 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 105.19 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 3.71 | Calculated using Price: 389.85 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.61 Cr. | 16,082,319 Shares |
FaceValue | 10 | |
About Kilitch Drugs (India) Ltd. | ||
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place. |
1 Day |
|
-0.06% |
1 Week |
|
+10.78% |
1 Month |
|
-6.99% |
3 Month |
|
+4.03% |
6 Month |
|
+57.24% |
1 Year |
|
+168.47% |
2 Year |
|
+132.04% |
5 Year |
|
+103.42% |
10 Year |
|
+2066.39% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -0.25 | -9.91 | -8.59 | 4.95 | 3.36 | 0.71 | 3.09 | 4.73 | 5.86 | |
Return on Capital Employed (%) | -0.74 | -10.11 | -8.69 | 6.08 | 7.59 | 1.95 | 4.4 | 7.26 | 10.26 | |
Return on Assets (%) | -0.19 | -9.25 | -7.86 | 4.36 | 2.85 | 0.59 | 2.19 | 3.03 | 3.89 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 120 | 109 | 101 | 112 | 121 | 118 | 127 | 139 | 152 | 167 | |
Non Curr. Liab. | -1 | -1 | -2 | -2 | -1 | -1 | -1 | -1 | -2 | -3 | |
Curr. Liab. | 7 | 8 | 12 | 15 | 20 | 22 | 73 | 69 | 69 | 70 | |
Minority Int. | 1 | 2 | 2 | 2 | 1 | -1 | -1 | ||||
Equity & Liab. | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 218 | 234 | |
Non Curr. Assets | 79 | 68 | 62 | 63 | 78 | 86 | 122 | 94 | 91 | 91 | |
Curr. Assets | 47 | 47 | 49 | 63 | 65 | 56 | 80 | 114 | 126 | 144 | |
Misc. Exp. not W/O | 0 | 0 | |||||||||
Total Assets | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 218 | 234 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 19 | 21 | 29 | 51 | 82 | 53 | 69 | 114 | 140 | 155 | |
Other Income | 3 | 3 | 1 | 3 | 5 | 5 | 3 | 3 | 3 | 5 | |
Total Income | 22 | 24 | 30 | 54 | 88 | 58 | 71 | 117 | 143 | 160 | |
Total Expenditure | -21 | -25 | -29 | -46 | -76 | -53 | -63 | -104 | -122 | -132 | |
PBIDT | 1 | -2 | 1 | 9 | 11 | 5 | 8 | 13 | 21 | 28 | |
Interest | 0 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -5 | -6 | |
Depreciation | -2 | -10 | -10 | -2 | -2 | -2 | -2 | -2 | -4 | -3 | |
Taxation | 1 | 0 | 0 | -1 | -5 | -1 | -1 | -3 | -4 | -6 | |
Exceptional Items | |||||||||||
PAT | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 13 | |
Minority Interest | 0 | 1 | 2 | 2 | |||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 7 | 10 | 15 | |
Adjusted EPS | 0 | -8 | -7 | 4 | 2 | 1 | 2 | 5 | 7 | 9 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | |
Cash Fr. Inv. | 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | |
Cash Fr. Finan. | -9 | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | -1 | |
Net Change | 2 | -39 | -2 | 0 | 2 | 3 | -5 | 10 | -2 | 10 | |
Cash & Cash Eqvt | 12 | 5 | 3 | 2 | 5 | 8 | 3 | 13 | 10 | 20 |
Tue, 26 Mar 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate We hereby inform you that we have received intimation from RTA regarding loss of share certificate by Ms. Nitaben Shah |
Tue, 26 Mar 2024
Closure of Trading Window The trading window for dealing in securities of the Company will remain closed for all the designated person of the Company and their immediate relatives with effect from Monday 1st April 2024 till expiry of 48 hours after declaration of the financial results for the quarter ended 31st March 2024 |
Thu, 21 Mar 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding loss of share certificate as per intimation received from RTA |
Thu, 28 Mar 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Above Last Week High |
High Increase in 6 Months |